StepStone Group’s Akero Therapeutics AKRO Stock Holding History

StepStone Group’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-9,389	Closed	-$199K	–	6
2020 Q1	$199K	Buy	+9,389	New	+$201K	1.15%	8

Other funds holding AKRO

ALSV

ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group's AKRO Position: Q2 2020 in Review

StepStone Group sold out of Akero Therapeutics (AKRO) in Q2 2020, closing a stake of 9,389 shares — an estimated $199K sold.

StepStone Group first reported a position in AKRO in Q1 2020 and held it in 1 quarter. The position peaked at $199K in Q1 2020. 79 funds tracked by Wall St. Rank hold AKRO as of Q2 2020.

StepStone Group reported no remaining Akero Therapeutics position as of Q2 2020 after selling out during the quarter.
StepStone Group sold 9,389 Akero Therapeutics shares in Q2 2020, an estimated $199K.
StepStone Group first reported a position in Akero Therapeutics in Q1 2020 and held it in 1 quarter.
StepStone Group's Akero Therapeutics position peaked at $199K in Q1 2020.
79 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2020.

Based on StepStone Group's 13F filing for Q2 2020, filed 7 Aug 2020.